Detalhe da pesquisa
1.
Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
Transpl Int
; 30(12): 1275-1283, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801959
2.
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study.
Clin Kidney J
; 12(2): 196-205, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30976396
3.
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
J Nephrol
; 30(1): 127-134, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26995002
4.
A Convenient Enzymatic Route to Optically Active l-Aminoindan-2-ol: Versatile Ligands for HIV-1 Protease Inhibitors and Asymmetric Syntheses.
Synthesis (Stuttg)
; 1997(5): 541-544, 1997 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30393402
5.
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Antimicrob Agents Chemother
; 47(10): 3123-9, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14506019